Leukotriene-receptor antagonists (LTRAs) are a class of medications used for treating allergic airway diseases, including asthma and allergic rhinitis. 1 Over the years, the US Food and Drug Administration has monitored postmarketing data about the potential harm of neuropsychiatric events (NEs) associated with montelukast, the first type of LTRAs, and issued boxed warnings about serious NEs associated with montelukast use in 2020. 2 However, evidence regarding the risk of NEs associated with LTRAs has been conflicting. 3-5 To the best of our knowledge, no previous studies have reported the association of exposure to LTRAs during pregnancy with the risk of NEs in offspring. The present cohort study aimed to address this research question.
Date:
2023-03-07
Relation:
JAMA Network Open. 2023 Mar 07;6(3):Article number e231934.
